Sarepta Therapeutics reported $-28.46M in Net Income for its fiscal quarter ending in September of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 53.52M 22.02M Sep/2026
Agios Pharmaceuticals USD -100.7M 1.59M Jun/2026
Alnylam Pharmaceuticals USD 2.17B 2B Sep/2026
Amgen USD 3.86B 1.49B Sep/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
Capricor Therapeutics USD -30.17M 5.6M Dec/2025
Daiichi Sankyo JPY 82.9B 14.26B Sep/2026
Eli Lilly USD 7.1B 301M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
Incyte USD -784.8M 1.37B Sep/2026
Insmed USD -13.24M 150.32M Jun/2026
Ionis Pharmaceuticals USD -87M 27.65M Sep/2026
Moderna USD 162M 944M Sep/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD 3.24B 3.49B Sep/2026
PTC Therapeutics USD 83.5M 86.3M Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR 3.02B 2.68B Sep/2026
Sarepta Therapeutics USD -28.46M 23.57M Sep/2026
Tectonic Therapeutic USD -22.28M 2.96M Jun/2026
Ultragenyx Pharmaceutical USD -118M 26M Sep/2026
Vertex Pharmaceuticals USD 653.6M 446.2M Sep/2026